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THE acute phase response is a systemic reaction to
inflammatory processes characterized by multiple
physiological adaptations, including the hepatic
synthesis of acute-phase proteins. In humans, serum
amyloid A (SAA) is one of the most prominent of
these proteins. Despite the huge increase of serum
levels of SAA in inflammation, its biological role
remains to be elucidated, even though SAA is un-
doubtedly active in neutrophils. In a previous study,
we reported that SAA induces the release of tumor
necrosis factor-a, interleukin (IL)-1b and IL-8 from
human blood neutrophils. Here, we extend our ear-
lier study, focusing on the effect of SAA on neutrophil
IL-8 transcription and on the signaling pathways
involved. We demonstrate herein that SAA, in rela-
tively low concentrations (0.4 
/100 mg/ml) compared
with those found in plasma in inflammatory condi-
tions, induces a dose-dependent release of IL-8 from
neutrophils. The p38 mitogen-activated protein ki-
nase inhibitor SB 203580 inhibits the IL-8 mRNA
expression and the release of protein from neutro-
phils. The release of IL-8 from SAA-stimulated neu-
trophils is strongly suppressed by the addition of N-
acetyl-L-cysteine, a-mercaptoethanol, glutathione,
and dexamethasone. SAA also induces IL-8 expres-
sion and release from monocytes. In conclusion, SAA
appears to be an important mediator of the inflam-
matory process, possibly contributing to the pool of
IL-8 produced in chronic diseases, which may play a
role in degenerative diseases.
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Introduction
Interleukin (IL)-8, the most well-characterized mem-
ber of the CXC-chemokine subfamily, plays a central
role in inflammatory processes.
1 A wide variety of cell
types, including neutrophils and cells of monocyte
lineage, release IL-8 upon exposure to bacterial
products and inflammatory cytokines.
2 4 The che-
motactic and stimulatory activities of IL-8 in blood
cells lead to the recruitment of a great number of
neutrophils and other immune cells to the inflamma-
tory site. Although cell recruitment is essential in
overcoming infectious processes, the uncontrolled
release of IL-8, and hence the uncontrolled influx of
inflammatory cells, is associated with the pathogen-
esis of various diseases.
5,6 IL-8 levels in plasma or
biological inflammatory fluids are often correlated
with the severity of the disease and the outcomes of
the patients. Accordingly, studies identifying stimuli
for IL-8 production and the signaling events involved
in this process are of significant interest in gaining a
greater understanding of inflammatory diseases.
Serum amyloid A (SAA) is a 12-kDa protein
synthesized by the liver during microbial infections
and inflammatory diseases.
7,8 In these conditions, the
serum concentration of SAA may reach levels up to
1000-fold greater than those found in the non-
inflammatory state. Although the concentration of
SAA in serum during inflammations is considerably
enhanced, its role is uncertain. In addition to the
hepatic synthesis of SAA, macrophages,
9 smooth
muscle cells and endothelial cells
10 can also synthe-
size SAA. Furthermore, SAA has been found in
atherosclerotic lesions
11 and in the brain of Alzheimer
patients.
12 These findings indicate a localized pro-
duction and action of SAA, emphasizing the impor-
tance of this protein in inflammations.
In a previous study, we reported that SAA induces
the release of tumor necrosis factor (TNF)-a, IL-1b
and IL-8 from human blood neutrophils.
13 Here, we
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173extend our earlier study, focusing on the effect of
SAA on neutrophil IL-8 transcription and on the
signaling pathways involved. Furthermore, we stu-
died the effect of SAA on the expression of IL-8 m-
RNA and on the release of protein in monocytes.
Materials and methods
Bovine fetal serum, dextran, ethylenediamine tetra-
acetic acid, Hepes, Histopaque†, lipopolysaccharide
(LPS) (Escherichia coli 026:B6), penicillin, N-acetyl-L-
cysteine, glutathione, 2-mercaptoethanol, dexa-
methasone, polymixin-B, pertussis toxin, RPMI 1640
supplemented with L-glutamine, sodium bicarbonate
and streptomycin used in this study were supplied by
Sigma Chemical Co., St. Louis, MO, USA. The
recombinant human SAA utilized came from Pepro-
tech Inc., Rocky Hill, NJ, USA. The SAA was
essentially endotoxin free, as indicated by a Limulus
Amebocyte Lysate test (for the concentrations of SAA
used in our experiments, 17 and 100 mg SAA, the level
of endotoxin was lower than 4 ng/ml) and by a
polymyxin B assay.
14 The drugs PD 98059 and SB
203580 were supplied by Calbiochem Novabiochem
Corp., San Diego, CA, USA. Both were solubilized in
dimethylsulfoxide (DMSO), resulting in a final con-
centration of DMSO of less than 0.1% per assay. This
amount of DMSO affected neither the mRNA expres-
sion nor the release of L-8. All other reagents and
media were dissolved in pyrogen-free water for
clinical use.
Cell purification and culture
Purified neutrophil preparations ( /98.5%) were
isolated, as previously described, from the buffy
coat
15 or peripheral blood
13 of healthy donors, both
under endotoxin-free conditions. Monocytes were
isolated from the peripheral blood of healthy donors
by Percoll gradient.
16
IL-8 protein assay
Neutrophils (2.5 /10
6cells/ml) suspended in RPMI
1640 and supplemented with 0.3 g/l glutamine, 2.32
g/l Hepes, 2 g/l sodium bicarbonate, 100 mg/ml
streptomycin, 100 IU/ml penicillin and 10% low
endotoxin fetal serum were cultured at 378C and
5% CO2, with and without SAA (0.4 /100 mg/ml).
After 2 /24 h, the supernatants were collected and
frozen at 5/  /408C until the IL-8 was determined by
enzyme-linked immunosorbent assay (Quantikine,
R&D System, Minneapolis, MN, USA).
The experiments with mitogen-activated protein
kinase (MAPK) inhibitors included the use of 50 mM
PD 98059 [a MAPK extracellular signal-regulated
kinase kinase (MEK-1) inhibitor]
17,18 or of 10 mMS B
203580 (a p38 MAPK inhibitor).
19 These inhibitors
were pre-incubated with neutrophils for 15 min
before the addition of SAA and then cultured for 24
h. Neutrophils treated with these concentrations of
inhibitors displayed no change in their exclusion of
Trypan blue and no leakage of cytosolic lactic acid
dehydrogenase. The SB 203580 and PD 98059 were
solubilized in DMSO, resulting in a final concentra-
tion of DMSO of less than 0.1% in the assay. This
amount of DMSO did not affect the mRNA expression
or release of L-8.
SAA-activated neutrophils were also incubated
with dexamethasone (1 mM), N-acetyl-L-cysteine
(0.3 mM), glutathione (10 mM) and 2-mercaptoetha-
nol (14 mM). Neutrophils treated with these concen-
trations of inhibitors showed no change in their
exclusion of Trypan blue, leaking no cytosolic lactic
acid dehydrogenase.
IL-8 was quantified in the supernatant of mono-
cytes (2.5 /10
5cells/ml), which were kept under the
same conditions as those described for neutrophils
and cultured for 24 h in the presence of SAA (17 mg/
ml) or LPS (1 mg/ml).
RNA isolation and northern blot analysis
Neutrophils (1.0 /10
7 cells/ml) and monocytes
(5.0 /10
6cells/ml) were cultured in the presence of
SAA (40 mg/ml) for different lengths of time (2, 6 and
21 h). Cell-free supernatants were discarded and total
RNA was extracted from the pellets, using the
guanidinium isothiocyanate method, and processed
for northern blot analysis, as previously described.
15
Probes were prepared using the Random Primer
Labeling Kit (Gibco BRL, Life Technologies, Gaithers-
burg, MO, USA). The hybridization signals were
estimated by scan and quantification, using the levels
of actin for normalization. The absence of monocyte
mRNA contamination in neutrophils was confirmed
by the lack of hybridization with an IL-6 cDNA probe,
as recommended by Wang et al.
20
The statistical analysis consisted of one-way ana-
lysis of variance with the Student /Newman /Keuls
Multiple Comparisons test.
Results
Neutrophil viability, tested by the Trypan blue exclu-
sion assay, was found to be unaltered in 24 h cultures
in the presence of SAA. Human neutrophils incu-
bated with SAA released considerable amounts of IL-
8 in 24 h cultures (Fig. 1). The amount of IL-8
released depended on the concentration of SAA.
Although significant variations are expected in IL-8
release, depending on the neutrophil preparation, a
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8 release and saturation was reached at close to 40
mg/ml SAA (Fig. 2). It is important to note that, in the
range assayed here (0.4 /100 mg/ml), the concentra-
tions of SAA were much lower than those present in
serum in acute phase conditions (up to 400 mg/ml).
21
Neutrophils release IL-8 upon exposure to different
classes of stimuli (e.g. bacterial products such as
bacterial LPS). The presence of two or more stimuli
may induce synergic or opposing effects that are
important in vivo. Because serum SAA has been
found to increase during bacterial infection, we
evaluated the combined effect of SAA and LPS on
the release of IL-8 by neutrophils. Mutual interference
between the effects of LPS and SAA was not
observed, since the resulting amount of IL-8 release
in cells treated with them was apparently additive
(Fig. 3).
To determine the IL-8 mRNA expression levels,
northern blots were performed using neutrophils
stimulated with SAA. Although no IL-8 protein was
detected in the supernatant of SAA-stimulated neu-
trophils after 2 h of incubation, the levels of IL-8
mRNA were higher than that found in the control cell
(Fig. 4). IL-8 mRNA levels are kept high for prolonged
exposure to SAA. This temporal pattern of IL-8
expression and release resembles that described for
LPS-stimulated neutrophils and differs considerably
from that induced by formyl-methionyl-leucyl-
phenylalanine (fMLP).
22
Members of the MAPK family become phosphory-
lated in response to diverse extracellular stimuli
23
and may be involved in the signaling that regulates
IL-8 expression.
24 However, it is also generally
accepted that distinct stimuli able to carry the same
response may use different intermediate pathways.
To evaluate the effect of two specific MAPK inhibitors
on SAA-stimulated IL-8 expression and release, we
added the inhibitors PD 98059 and SB 203580, which
target the upstream effector of extracellular signal-
regulated protein kinase (MEK-1)
17,18 and the p38
kinase,
19 respectively. At concentrations previously
used to inhibit cytokine expression and release
provoked by other stimuli,
24 SB 203580 and PD
98059 (to a lesser degree) decreased IL-8 mRNA
levels (Fig. 5). Both these inhibitors had an inhibitory
effect on the release of IL-8 protein (Fig. 6). These
results indicate the activation of MAPK pathways by
SAA, as demonstrated with other stimuli in
neutrophils.
23 25
The effect of the antioxidants N-acetyl-L-cysteine,
2-mercaptoethanol and glutathione, and the anti-
inflammatory dexamethasone on SAA-stimulated IL-
8 release was investigated. Although these com-
FIG. 1. IL-8 protein levels found in the supernatant of 2 and
24 h cultures of neutrophils (2.5 /10
6 cells/ml) in the
absence and with the presence of SAA (17 and 100 mg/ml
SAA). The data represent the average9 /standard deviation of
at least ﬁve experiments.
FIG. 2. IL-8 protein levels found in the supernatant of 24 h
cultured neutrophils (2.5 /10
6 cells/ml) incubated with dif-
ferent concentrations of SAA. The data represent the
average9 /standard deviation of at least ﬁve experiments.
FIG. 3. Effect of the combined addition of SAA (17 mg/ml) plus
LPS (1 mg/ml) on the release of IL-8 in the supernatant of 24 h
cultured neutrophils (2.5 /10
6 cells/ml). The data represent
the average9 /standard deviation of at three experiments (***
pB/0.001).
FIG. 4. IL-8 mRNA levels determined by northern blots of
2.0 /10
7 neutrophils stimulated for 2, 6 and 21 h with SAA
(40 mg/ml). Lower part: average9 /standard deviation of the
normalized data using the corresponding actin signals of
three experiments.
SAA-induced IL-8 expression in neutrophils and monocytes
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share an inhibitory effect on the nuclear transcription
factor nuclear factor-kB.
26 29 These four compounds
caused a strong reduction in the amount of IL-8
released from SAA-stimulated neutrophils (Fig. 7).
Finally, although it is clear from this study that SAA
induces the expression and release of IL-8 from
human blood neutrophils, it was important to deter-
mine whether this effect was restricted to neutrophils
or whether it might extend to other cellular types. We
observed that monocytes also respond to SAA
increasing IL-8 expression and release. Figs. 8 and 9
illustrate the effect of SAA on monocytes in compar-
ison with LPS.
Discussion
The acute phase response is a systemic reaction to
inflammatory processes characterized by multiple
physiological adaptations, including the hepatic
synthesis of acute-phase proteins.
30 In humans, SAA
is one of the most prominent of these proteins.
30 33
Despite the huge increase of serum levels of SAA in
inflammation, its biological role remains to be
elucidated, even though SAA is undoubtedly active
in neutrophils and monocytes. SAA affects neutrophil
degranulation, phagocytosis, killing activity,
34 and
neutrophil and monocyte cytokine release (see
reference 13 and the present study).
In neutrophils, SAA binds to the G-protein-coupled
receptor FPRL 1.
35 The responses mediated by G-
protein-coupled receptors involve both the stimula-
tion of conventional second-messenger-generating
systems, and the functional integration of the intra-
cellular signaling network.
36 The association of SAA
with the FPRL 1 receptor is probably involved in the
intracellular Ca
2  mobilization and produces some
of the biological effects described for SAA. In a recent
study simultaneous to our own, He et al.
37 showed
that the production of IL-8 induced by SAA in
neutrophils is also triggered by this receptor. As
described for a variety of agonists acting on G-
FIG. 6. Effect of SB 203580 (10 mM) and PD 98059 (50 mM) on
SAA-induced IL-8 release in the supernatants of 24 h
neutrophil cultures (2.5 /10
6 cells/ml). The neutrophils were
preincubated with the inhibitors 15 min before the addition
of SAA (17 mg/ml). The data represent the average9 /standard
deviation of ﬁve experiments (*** pB/0.001).
FIG. 7. Effect of dexamethasone (DEX) (1 mM), N-acetyl-L-
cysteine (NAC) (0.3 mM), 2-mercaptoethanol (ME) (14 mM)
and glutathione (GSH) (10 mM) on SAA-induced IL-8 release
in the supernatants of 24 h neutrophil cultures (2.5 /10
6
cells/ml). The neutrophils were preincubated with these
compounds 15 min before the addition of SAA (17 mg/ml).
The data represent the average9 /standard deviation of ﬁve
experiments (*** pB/0.001).
FIG. 8. IL-8 mRNA levels determined by northern blots of
5.0 /10
6 monocytes stimulated for 2 and 6 h with SAA (40
mg/ml) or LPS (100 ng/ml). The data are representative of
three experiments.
FIG. 9. IL-8 protein levels found in the supernatant of 24 h
cultured monocytes (2.5 /10
5 cells/ml) incubated with SAA
(17 mg/ml) or LPS (1 mg/ml). The data represent the average9 /
standard deviation of at least ﬁve experiments (* pB/0.05
and ** pB/0.01).
FIG. 5. Effect of SB 203580 (10 mM) and PD 98059 (50 mM) on
IL-8 mRNA levels determined by northern blots of 2.0 /10
7
neutrophils stimulated for 2 h with SAA (40 mg/ml). The
neutrophils were pre-incubated with the inhibitors 15 min
before the addition of SAA. The data are representative of
three experiments.
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38,39 the activation of
MAPK pathways could be operative from the FRLP
1 receptor. Here, we observed that SAA in relatively
low concentrations compared with the plasma SAA
concentration found in inflammatory conditions is
able to induce the release of IL-8, and that MAPK
pathways apparently play an important role in this
process. A clear effect of the p38 MAPK inhibitor SB
203580 is observed in both neutrophil IL-8 mRNA
expression and protein release promoted by SAA.
The inhibitory effect promoted by PD 98059 was
much more evident at the protein level than at the
mRNA level, which seems to be characteristic of this
compound, since the same behavior was observed in
the induction of TNF-a promoted by LPS in mono-
cytes.
40
The inhibitory effect of the antioxidants and
dexamethasone observed on SAA-induced IL-8 re-
lease from neutrophils is consistent with the general
mechanism of nuclear factor-kB activation. This
finding may be relevant in the future to support the
therapeutic use of antioxidants in chronic diseases in
which serum SAA is higher than under normal
physiological conditions.
All normal immune responses, including innate
and adaptive immunity, are self-limited. For instance,
in most acute inflammations, the hepatic synthesis of
SAA wanes over time. In a broad sense, the return to
homeostasis is essential to prevent uncontrolled
tissue damage. It is therefore difficult to interpret
the biological significance and impact on the pro-
gression of disease of persistently high levels of SAA
in some chronic diseases, such as diabetes,
41 can-
cer,
42 atherosclerosis
43 and rheumatic diseases.
44 The
intriguing positive correlation existing between high
SAA serum levels and coronary artery disease
43 and
the presence of SAA in human atherosclerotic le-
sions
11 and in the brain of Alzheimer patients
12
suggests that SAA plays a role in the genesis and
progression of chronic diseases. IL-8 seems to be
closely involved in angiogenesis
45 and atheroma
plaque formation.
46 The SAA induction of IL-8 may,
for instance, provide a link between the rise in SAA
serum levels and the development of coronary
disease. The same rationale could be used for long-
term conditions that give rise to basal increasingly
higher SAA serum levels than those found in healthy
individuals, where a constant stimulus for the release
of proinflammatory cytokines by responsive cells
may be provided.
In conclusion, SAA appears to be an important
mediator of the inflammatory process and may
contribute to the pool of IL-8 produced in chronic
diseases, which may play a role in degenerative
diseases. As is the case with IL-8, the serum level of
SAA is associated with the severity of the disease.
21 In
our hypothesis, the deleterious effect of SAA is
partially mediated by the release of IL-8 and other
inflammatory cytokines. It is conceivable that some of
the activities described for SAA are mediated by these
cytokines rather than being a direct effect of SAA.
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